SCHEMBL30965448

SCHEMBL30965448

CC(C)C(=O)Nc1ccc(-c2ccc(-c3nc4ccc(Cl)cc4o3)cc2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 5/20 0.81
▸ SENP7 Q9BQF6 4/20 0.81
▸ NPC1 O15118 9/20 0.69
▸ RAB9A P51151 9/20 0.69
▸ ALDH1A1 P00352 6/20 0.69
▸ SMN1; SMN2 Q16637 5/20 0.69
▸ HSD17B10 Q99714 4/20 0.69
▸ KDM4E B2RXH2 4/20 0.69
▸ KMT2A Q03164 2/20 0.69
▸ HPGD P15428 3/20 0.61
▸ TP53 P04637 2/20 0.61
▸ GAA P10253 2/20 0.61
▸ THRB P10828 1/20 0.61
▸ TSHR P16473 1/20 0.61
▸ NPSR1 Q6W5P4 1/20 0.61
▸ POLB P06746 3/20 0.61
▸ TDP1 Q9NUW8 1/20 0.61
▸ MEN1 O00255 1/20 0.59
▸ USP2 O75604 2/20 0.56
▸ LMNA P02545 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24106598 1.00 CASP3 (0.81) CASP3SENP7NPC1RAB9AALDH1A1
SCHEMBL2249425 0.99 CASP3 (0.83) CASP3SENP7NPC1RAB9AALDH1A1
SCHEMBL2242299 0.92 CASP3 (0.75) CASP3SENP7NPC1RAB9AALDH1A1
SCHEMBL2245760 0.89 CASP3 (1.00) CASP3SENP7NPC1RAB9AALDH1A1
SCHEMBL2250007 0.86 NPC1 (0.76) CASP3SENP7NPC1RAB9AALDH1A1
SCHEMBL2247759 0.85 RAB9A (0.81) CASP3SENP7NPC1RAB9AALDH1A1
SCHEMBL30789006 0.85 CASP3 (0.82) CASP3SENP7NPC1RAB9AALDH1A1
SCHEMBL23748388 0.85 CASP3 (0.82) CASP3SENP7NPC1RAB9AALDH1A1
SCHEMBL2243398 0.85 CASP3 (0.87) CASP3SENP7NPC1RAB9AALDH1A1
SCHEMBL23748365 0.84 CASP3 (0.84) CASP3SENP7NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations ALBERT EINSTEIN COLLEGE OF MEDICINE 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations SQSTM1, MCL1, HSPA2 CASP3 1753/4885SENP7 1775/4885NPC1 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback